RT Journal
A1 Onuigbo MC
T1 ALlhat findings revisited in the context of subsequent analyses, other trials, and meta-analyses
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2009
FD October 26
VO 169
IS 19
SP 1806
OP 1818
DO 10.1001/archinternmed.2009.371
UL http://dx.doi.org/10.1001/archinternmed.2009.371
AB 

			I read with interest and curiosity the recent revisitation of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) trial by Wright et al.1 They concluded that current evidence confirmed that neither α-blockers, angiotensin-converting enzyme inhibitors (ACEIs), nor calcium channel blockers (CCBs), surpass thiazide-type diuretics (at an appropriate dosage) as initial therapy for reduction of cardiovascular or renal risk.1 We cannot agree more, especially in light of recent trials including the ONTARGET trial2 and new insights into plausible benefits of cardioprotection and renoprotection using different antihypertensive classes.3- 4